Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2043 articles with Johnson & Johnson Family of Companies
-
In August, Pfizer filed with the U.S. Food and Drug Administration (FDA) accusing Amgen and Roche of using social media to mislead doctors and patients about biosimilars and their effectiveness.
-
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
-
Although race is thought of as a social concept, ‘there’s growing evidence that, whether for environmental or genetic reasons, drugs may have different effects on different populations.’
-
New Phase 3 Data Show Single Dose Of STELARA® (ustekinumab) Induces Clinical Remission And Response In Adults With Moderate To Severe Ulcerative Colitis
10/9/2018
Janssen presents 8-week induction data from pivotal Phase 3 UNIFI study during plenary session at the American College of Gastroenterology Annual Scientific Meeting 2018.
-
Opioid manufacturers have been the target of thousands of lawsuits from state and local governments seeking to reclaim funds that have been spent on addressing treatment for opioid abuse and overdoses.
-
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
10/4/2018
Agreement expands breadth of Janssen's hepatitis B virus development portfolio
-
Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
10/4/2018
Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc.
-
In April, Dr. Robert Redfield, the new head of the CDC, boldly predicted that the AIDS epidemic can be defeated by 2025. This morning Merck, Janssen and Gilead all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
-
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
-
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
10/2/2018
Johnson & Johnson today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion.
-
3 Months After Launching a Phase Ib Trial, Janssen Terminates Collaboration Deal with Aduro Biotech
10/2/2018
Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers. -
Where will the next big idea in healthcare come from? Johnson & Johnson is counting on nurses.
10/1/2018
Johnson & Johnson Launches Nurses Innovate QuickFire Challenge to Bring Nurses' Ideas to Life
-
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
-
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
-
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
-
Johnson & Johnson Announces New Collaboration to Advance Novel Vaccine for MERS
9/27/2018
New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts
-
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
-
Johnson & Johnson Vision Showcases Latest Clinical Data and Eye Care Solutions at the ESCRS 2018 Annual Meeting
9/21/2018
Latest clinical data builds on the wealth of evidence supporting the safety, efficacy and overall benefits of TECNIS Symfony® IOLs for cataract patients
-
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
-
Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million
9/13/2018
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.